.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Dow
US Department of Justice
Baxter
Cipla
Harvard Business School
Express Scripts
Federal Trade Commission
Daiichi Sankyo
Chubb

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,155,718

« Back to Dashboard

Which drugs does patent 9,155,718 protect, and when does it expire?


Patent 9,155,718 protects ADVIL PM and is included in one NDA. There has been one Paragraph IV challenge on Advil PM.

This patent has eleven patent family members in ten countries.

Summary for Patent: 9,155,718

Title:Treatment of sleep disturbances
Abstract: The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.
Inventor(s): Cook; Graham D. (Midlothian, VA), Koch; Todd S. (Powhatan, VA), Giamalva; David H. (Glen Allen, VA), Bianco; Justin (Vineland, NJ), Fort; James J. (Midlothian, VA), Doyle; Geraldine (Chatham, NJ), Cooper; Steven (Denville, NJ)
Assignee: Wyeth LLC (New York, NY)
Application Number:14/504,159
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
PfizerADVIL PMdiphenhydramine hydrochloride; ibuprofenCAPSULE;ORAL021393-001Dec 21, 2005OTCYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,155,718

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,263,647Treatment of sleep disturbances► Subscribe
8,883,849Treatment of sleep disturbances► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,155,718

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2004521104► Subscribe
Japan4402882► Subscribe
Hong Kong1060045► Subscribe
Denmark1363608► Subscribe
European Patent Office1363608► Subscribe
Spain2251584► Subscribe
Japan2009203243► Subscribe
Germany60207383► Subscribe
MexicoPA03006364► Subscribe
Austria309797► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Daiichi Sankyo
Queensland Health
QuintilesIMS
Cerilliant
Farmers Insurance
Moodys
Cipla
Covington
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot